

HOKKAIDO UNIVERSITY

Title	Development of a time-resolved fluoroimmunoassay for salmonid insulin-like growth factor binding protein-2b
Author(s)	Izutsu, Ayaka; Habara, Shiori; Kaneko, Nobuto; Tadokoro, Daiji; Hara, Akihiko; Shimizu, Munetaka
Citation	General and Comparative Endocrinology, 340 https://doi.org/10.1016/j.ygcen.2023.114305
Issue Date	2023-05-12
Doc URL	http://hdl.handle.net/2115/92600
Rights	© <2023>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	http://creativecommons.org/licenses/by-nc-nd/4.0/
Type	article (author version)
File Information	ForHUSCAP_Izutsu23.pdf

Instructions for use

Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP

REVISED Manuscript (text UNmarked) Click here to view linked References

1 **Title:**

2 Development of a time-resolved fluoroimmunoassay for salmonid insulin-like growth factor
3 binding protein-2b

4

5 **Authors:**

6 Ayaka Izutsu[1], Shiori Habara[1], Nobuto Kaneko[2]†, Daiji Tadokoro[3], Akihiko Hara[4], and Munetaka
7 Shimizu[4,5]

8

9 [1]Graduate School of Environmental Science, Hokkaido University, Kita 10, Nishi 5, Kita-ku,
10 Sapporo, Hokkaido 060-0810, Japan

11 [2]Graduate School of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate, Hokkaido
12 041-8611, Japan

13 [3]FRD Japan, Co., Kazusa Kamatari 3-9-13, Kisarazu, Chiba 292-0818, Japan

14 [4]Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate, Hokkaido 041-
15 8611, Japan

16 [5]Field Science Center for Northern Biosphere, Hokkaido University, 3-1-1, Hakodate, Hokkaido
17 041-8611, Japan

18

19 *Corresponding author, e-mail: mune@fish.hokudai.ac.jp; office: +81-138-40-8897

20 † Present affiliation: Fisheries Technology Institute, Nansei Field Station, Japan Fisheries
21 Research and Education Agency, Minamiise, Mie 516-0193, Japan

22

23 **Abstract**

24 Insulin-like growth factor (IGF)-1 promotes the growth of vertebrates, and its binding proteins
25 (IGFBPs) regulate the activity of circulating IGF-1. Three IGFBPs, IGFBP-2b, -1a, and -1b, were
26 consistently detected in the circulatory system of salmonids. IGFBP-2b is thought to be the main
27 carrier of IGFs and promoter of IGF-1-mediated growth in salmonids. Currently, there are no
28 immunoassays for detecting IGFBP-2b. In this study, we developed a time-resolved
29 fluoroimmunoassay (TR-FIA) for IGFBP-2b detection in salmonid fishes. To establish TR-FIA,
30 we produced two recombinant trout (rt) IGFBP-2bs expressed, one with thioredoxin (Trx) and a
31 histidine (His) tag, and the other with His-tag only. We labeled both recombinant proteins with
32 Europium (Eu). Only Eu-Trx.His.rsIGFBP-2b cross-reacted with anti-IGFBP-2b, and the addition
33 of increasing amounts of Trx.His.rsIGFBP-2b replaced the binding, indicating its utility as a tracer
34 and assay standard. The addition of unlabeled salmon IGF-1 did not affect the binding of the
35 standard or sample. Serial dilution curves of sera from rainbow trout, Chinook salmon, and chum
36 salmon were parallel to those of the standard. The assay range (ED_{80}–ED_{20}) of the TR-FIA was
37 60.4 to 251.3 ng/ml, and its minimum detection limit of this assay was 21 ng/ml. The intra- and
38 inter-assay coefficients of variation were 5.68% and 5.65%, respectively. Circulating IGFBP-2b
39 levels in fed rainbow trout were higher than those in fasted fish and were correlated with
40 individual growth rates. This TR-FIA is useful for further exploring the physiological responses
41 of circulating IGFBP-2b and evaluating the growth status of salmonids.

42

43 **Keywords**

44 growth index, hormone, immunoassay, salmonids

45 **1. Introduction**

46 Insulin-like growth factor (IGF)-1 is a 7.5 kDa polypeptide structurally similar to proinsulin and
47 plays an important role in the promotion of growth in vertebrates. IGF-1 exerts its effect through
48 endocrine, paracrine, and autocrine activities (Daughaday and Rotwein, 1989; Wood et al., 2005).
49 Endocrine IGF-1 is mainly secreted from the liver upon stimulation by growth hormone (GH) and
50 mediates the growth-promoting actions of GH on skeletal muscle and other tissues (Daughaday
51 and Rotwein, 1989; Ohlsson et al., 2009). Unlike insulin, IGF-1 in the circulation is stabilized by
52 IGF-binding proteins (IGFBPs). IGFBPs prolong the half-life of IGF-1 by protecting it from
53 glomerular filtration and enzymatic degradation and modulate the action of IGF-1 by regulating
54 its availability to the receptor (Rajaram et al., 1997; Bach, 2018; Clemmons, 2018).

55 Six IGFBPs, IGFBP-1–6, have been identified in mammals (Shimasaki and Ling,
56 1991; Rajaram et al. 1997; Bach, 2018). IGFBPs can either inhibit or promote IGF action,
57 depending on the type of IGFBP, post-translational modification, and cellular environment (Firth
58 and Baxter, 2002). Besides regulating IGF-1 availability, the IGF-independent action of IGFBPs
59 on cell growth has been reported in various mammalian cell types (Mohan and Baylink, 2002).
60 Among them, IGFBP-3 is a major carrier of IGFs in the mammalian circulatory system (Rajaram
61 et al., 1997). IGFBP-3 carries approximately 80% of the circulating IGF-1 by forming a ternary
62 complex with IGF-1 and acid-labile subunit (ALS) (Baxter and Martin, 1989). The ternary
63 complex creates a large pool of circulating IGF-1, and when needed, specific enzymes, such as
64 metalloproteinases, partially degrade IGFBP-3 and make IGF-1 available to the receptor (Ranke,
65 2015). IGFBP-3 is a promoter of IGF-1-mediated growth.

66 All six types of IGFBPs have been identified in teleosts (Ocampo Daza et al., 2011;
67 Macqueen et al., 2013; de la Serrana and Macqueen, 2018). Due to an extra 3rd round of whole-
68 genome duplication (WGD) in teleosts, there are two paralogs of each member of the IGFBP
69 family, except IGFBP-4 (Ocampo Daza et al., 2011). In addition, salmonids experience
70 autotetraploidization and possess up to four subtypes of IGFBPs (Macqueen et al., 2013). The
71 retention of these gene repertoires may have a selective advantage by partitioning their original
72 functions and fine-tuning their growth pace (de la Serrana and Macqueen, 2018). Three IGFBP
73 bands have been consistently detected in the circulatory system of teleosts by ligand blotting using
74 labeled human IGF-1 (Kelley et al., 1992, 2001; Upton et al., 1993; Shimizu and Dickhoff, 2017).
75 One of the bands at 40–50 kDa was thought to be fish IGFBP-3 because its molecular weight,
76 post-translational modification (i.e., *N*-glycosylation), and physiological regulation were similar
77 to those of mammalian IGFBP-3. However, in Chinook salmon (*Oncorhynchus tshawytscha*), it

78 has been identified as a subtype of IGFBP-2 (i.e., IGFBP-2b) while two others being IGFBP-1a
79 and -1b (Shimizu et al., 2003, 2011a,b). In contrast, there is no evidence of the ternary complex
80 despite the presence of genes and transcripts for *igfbp-3* and *als* in teleosts (Shimizu and Dickhoff,
81 2017). These findings suggest that IGFBP-2b, and not IGFBP-3, is a major carrier of circulating
82 IGF-1, at least in salmonids (Shimizu et al., 2003, 2011b; Shimizu and Dickhoff, 2017).
83 A radioimmunoassay (RIA) for salmon IGFBP-2b was developed using purified
84 proteins as antigens, radiolabeled tracers, and assay standards (Shimizu et al., 2003).
85 Quantification of circulating IGFBP-2b in salmonids has revealed that its level is high in fish fed
86 a high ration or treated with GH, as seen in mammalian IGFBP-3 (Shimizu et al., 2003). Moreover,
87 there is a positive correlation between circulating IGFBP-2b levels and individual growth rates in
88 post-smolt coho salmon (*O. kisutch*) in freshwater (Beckman et al., 2004a,b). These studies
89 suggest that IGFBP-2b can be used as a positive index of growth in salmonids. However, RIA is
90 currently not being operated because of the shortage of purified protein for use as a tracer and
91 assay standard (Shimizu, personal communication). Moreover, RIAs, in general, have been
92 replaced by non-radioactive assays.
93 Rainbow trout (*O. mykiss*) is an important species for aquaculture and the second most
94 cultured salmonid in the world (FAO, 2020). This species is cultured under a variety of rearing
95 conditions, including salinity, water temperature, photoperiod, and fish density. In addition,
96 alternative diets such as plant protein-based diets are being developed for sustainable salmon
97 aquaculture (Jalili et al., 2013; Hua et al., 2019). These rearing conditions and new diets may
98 cause rainbow trout to grow under suboptimal conditions. Therefore, monitoring the growth status
99 of rainbow trout is particularly important in aquaculture.
100 Our previous study using ligand blotting revealed that circulating IGFBP-2b in
101 immature rainbow trout was positively correlated with individual growth rate, as was the case for
102 circulating IGF-1, supporting its utility as a growth index in rainbow trout (Izutsu et al., 2022).
103 The objective of this study was to develop a time-resolved fluoroimmunoassay (TR-FIA) for
104 trout/salmon IGFBP-2b using recombinant rainbow trout IGFBP-2b.
105
106 **2. Materials and Methods**
107 *2.1. Production of recombinant rainbow trout IGFBP-2b1*
108 A cDNA encoding rainbow trout IGFBP-2b1 (GenBank Accession No. NM_ 001124649) was
109 used to express recombinant protein. The procedures followed for vector construction and protein
110 expression were as described by Tanaka et al. (2018). Briefly, the pET-32a(+) vector (Novagen,

111 Madison, WI, USA), which adds thioredoxin (Trx) and histidine (His)-tag (6 × His) at the N-
112 terminal region of the expressed recombinant protein, and the pET-16b vector (Novagen), which
113 adds only a His-tag, were used. The constructed plasmids (pET32a-Trx. His.rtIGFBP-2b1 and
114 pET16b-His. rtIGFBP-2b1) were transformed into the *Escherichia coli* strain Rosetta-gami
115 B(DE3)pLysS (Novagen). Recombinant protein expression was induced by adding isopropyl-β-
116 D-thiogalactoside (IPTG). Bacterial proteins were separated into soluble and insoluble fractions
117 using Bugbuster Protein Extraction Reagent (Novagen). The insoluble fractions containing
118 recombinant proteins were solubilized in urea and subjected to affinity chromatography using a
119 His-Bind Resin (Novagen) column. The eluate from the column was dialyzed against 20 mM
120 Tris-HCl, pH 8.0, containing 2% NaCl and urea was stepwise removed to facilitate correct
121 refolding.
122
123 *2.2. Electrophoresis, ligand blotting and immunoblotting*
124 Four micrograms of affinity-purified Trx.His.rtIGFBP-2b was separated by sodium dodecyl
125 sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 3% stacking gel and 12.5%
126 separating gel. The sample was treated with an equal volume of the sample buffer containing 2%
127 SDS and 10% glycerol with or without 5% 2-mercaptoethanol at 85 °C for 5 min. Gels were
128 placed in a solution of 50 mM Tris, 400 mM glycine, and 0.1% SDS at 8 mA for the stacking gel
129 and 12 mA for the separating gel until the bromophenol blue dye front reached the bottom of the
130 gel, and were stained with 0.1% Coomassie Brilliant Blue (CBB) R250 (Bio-Rad, Hercules, CA).
131 Molecular mass was estimated with Precision Marker (Bio-Rad).
132 IGF-binding ability of Trx.His.rtIGFBP-2b was assessed by ligand blotting with
133 digoxigenin-labeled human IGF-1 (DIG-hIGF-1) according to a previously described protocol
134 (Shimizu et al., 2000). Four hundred nanograms of the recombinant protein was separated by
135 SDS-PAGE and electroblotted onto a nitrocellulose membrane. The membrane was incubated
136 overnight with DIG-hIGF-1 (50 ng/ml) and then incubated with antibodies against DIG
137 conjugated horseradish peroxidase (HRP; Roche, Indianapolis, IN, USA) at a dilution of 2,000
138 for 1.5 h at room temperature (20–25 °C). IGFBP bands were visualized using enhanced
139 Chemiluminescence (ECL) Prime western blotting reagents (Amersham Life Science, Arlington
140 Heights, IL, USA) and ImageQuant LAS 500 (GE Healthcare, Uppsala, Sweden).
141 For immunoblotting, an electroblotted nitrocellulose memberane was incubated with
142 antiserum against purified Chinook salmon IGFBP-2b (Shimizu et al., 2003) at a dilution of
143 1:2,500 for 2 h at room temperature (20–25 °C). The membrane was then probed with goat anti-

144 rabbit IgG-HRP conjugate (Bio-Rad) at a dilution of 1:10,000 for 1 h at room temperature (20–
145 25 °C). Immunoreactive bands were visualized using the ECL reagents as described above.
146
147 *2.3. Preparation of tracer*
148 His.rtIGFBP-2b and Trx.His.rtIGFBP-2b were labeled with Europium (Eu)-Labeling Reagent (6
149 mM) using a DELFIA Eu-N1 ITC chelate labeling kit (PerkinElmer, Waltham, MA, USA)
150 according to the manufacturer's protocol, with optimization. Briefly, approximately 70 μg
151 recombinant protein in 20 mM Tris-HCl (pH 8.0) containing 0.5M NaCl was dialyzed against 50
152 mM sodium bicarbonate/sodium carbonate (pH 9.3) at 4 ℃. Trx.His.rtIGFBP-2b1 (70 μg in 80
153 μl) was mixed with 14 μl of 4 mg/ml Eu-N1-ITC chelate (1:60 molar ratio) and reacted overnight
154 at 4 ℃ under dark conditions. Eu-labeled His.rtIGFBP-2b1 and Trx.His.rtIGFBP-2b1 were
155 separated from the unreacted Eu-chelate by gel filtration using a Sephadex G-25 (Superfine;
156 Pharmacia Fine Chemicals, Uppsala, Sweden) column (10 × 80 mm). Samples were eluted by
157 applying 50 mM Tris-HCl (pH 7.8) containing 0.9% NaCl to the top of the gel, and 0.5 ml
158 fractions were collected manually. Time-resolved fluorescence and protein concentrations in each
159 fraction were measured using a Wallac ARVO X4 (PerkinElmer) and Pierce BCA Protein Assay
160 Kit (Thermo Fisher Scientific, Waltham, MA, USA), respectively.
161
162 *2.4. TR-FIA for IGFBP-2b*
163 A competitive method was employed in this study. A 96-well assay plate coated with goat anti-
164 rabbit IgG (DELFIA Yellow Plate; Perkin Elmer) was first washed with 200 μl DELFIA Wash
165 Buffer (Perkin Elmer), and 20 μl anti-Chinook salmon IGFBP-2b (Shimizu et al., 2003; 1:125)
166 and 120 μl standard (Trx.His.rtIGFBP-2b1) or serum was added to each well. The plate was sealed
167 and incubated overnight at 4 °C with shaking at 600 rpm on a shaker. On the next day, the plate
168 was flash centrifuged and 20 μl Eu-Trx.His.rtIGFBP-2b1 (1:5,500) was added to each well and
169 the plate was incubated overnight at 4 °C with shaking at 600 rpm. On the last day, the plate was
170 washed six times with 200 μl wash buffer, and 200 μl DELFIA Enhancement Solution
171 (PerkinElmer), which had been acclimated to room temperature before use, was added to each
172 well. The plate was shaken without sealing for 10 minutes at room temperature. Time-resolved
173 fluorescence was measured using a Wallac ARVO X4 multi-label counter (PerkinElmer).
174
175 *2.5. Biological validation*
176 IGFBP-2b levels in sera from fed, fasted, and refed immature rainbow trout were measured using

177 TR-FIA and LIFA for biological validation. Details of the rearing experiment have been described
178 by Izutsu et al. (2022). Briefly, three groups of underyearling rainbow trout (body weight: 265.4
179 ± 7.8 g) individually tagged using passive integrated transponder (PIT) tags (12.5 × 2.1 mm,
180 Biomark, Boise, ID, USA) were fed or fasted for 33 days or refed for 11 days after 22 days of
181 fasting. Sera collected on day 33 were used for the analyses. As stated in Izutsu et al. (2022),
182 Rearing and handling fish were carried out in accordance with the guidelines of the Hokkaido
183 University Animal Care and Use Committee (#30-3).
184
185 *2.6. Statistical analysis*
186 The results were analyzed by one-way ANOVA using JMP Pro 16 (SAS Institute Inc., Cary, NC,
187 USA). When significant effects were found, differences were further identified using Tukey's
188 honestly significant difference (HSD) test, with differences considered significant at $P < 0.05$.
189 Linear correlation analysis was also performed to determine the relationship between serum
190 IGFBP-2b levels and the growth rate or serum IGF-1 concentrations of individual trout.
191
192 **3. Results**
193 *3.1. Production of recombinant IGFBP-2b used for Eu-labeling*
194 Affinity-purified Trx.His.rsIGFBP-2b exhibited two bands around 46 kDa on SDS-PAGE (Fig.
195 1). One of the two bands had IGF-binding ability on ligand botting while the other did not. On
196 the other hand, both bands were immunostained with antiserum against IGFBP-2b on
197 immunoblotting (Fig. 1). Affinity-purifed His.rsIGFBP showed patterns similar to those of
198 Trx.His.rsIGFBP-2b (data not shown).
199
200 *3.2. Development of TR-FIA*
201 When the Eu-labeled proteins were separated from the unreacted Eu, Eu-Trx.His.rtIGFBP-2b
202 showed a clear peak in the pass-through fraction of gel filtration, whereas Eu-His. rtIGFBP-2b
203 showed no peak (Data not shown). Eu-Trx.His.rtIGFBP bound to anti-IGFBP-2b and showed
204 time-resolved fluorescence (data not shown). Thus, Eu-Trx.His.rtIGFBP-2b was used as a tracer
205 for further development of TR-FIA.
206 The utility of unlabeled Trx.His.rtIGFBP-2b and His.rtIGFBP-2b as assay standards
207 were examined in TR-FIA using Eu-Trx.His.rtIGFBP-2b (Fig. 2). Tracer binding was displaced
208 by competition with Trx.His.rtIGFBP-2b in a dose-dependent manner, which was parallel to the
209 serial dilution of rainbow trout serum. In contrast, His.rtIGFBP-2b was ineffective in displacing

210 tracer binding. Based on these results, Trx.His.rtIGFBP-2b was selected as the assay standard.

211 The addition of varying amounts of salmon IGF-1 (equivalent to 0.3 to 80 ng/ml) did
212 not affect the binding of the standard (equivalent to 209 ng/ml) and serum (equivalent to 386
213 ng/ml) (Fig. 3). The assay range (ED_{80}–ED_{20}) of the TR-FIA was 60.4 ± 3.3 to 251.3 ± 18.6 ng/ml,
214 and its minimum detection limit, defined as the mean of the zero standard minus two standard
215 deviations, was 21 ng/ml (n = 4). No displacement was observed in recombinant Atlantic salmon
216 IGFBP-1b with or without fusion partners, thioredoxin, or a histidine-tag (Maruoka et al.,
217 unpublished data) (Fig. 4a). The intra- and interassay coefficients of variation were 5.68% (n =
218 8) and 5.65% (n = 4), respectively. Recovery of Trx.His.rtIGFBP-2b added to rainbow trout serum
219 was 98.7% (n = 6). Serial dilutions of the sera from spawning Chinook salmon and adult chum
220 salmon were parallel to the standard curve (Fig. 4b).
221
222 *3.3. Biological validation*
223 Serum IGFBP-2b levels in fed, fasted, and refed rainbow trout were measured using TR-FIA and
224 compared with those semi-quantified by ligand blotting using labeled hIGF-1 as reported by
225 Izutsu et al. (2022). Serum IGFBP-2b levels measured using TR-FIA decreased after 33 days of
226 fasting and remained low after 22 days of fasting, followed by 10 days of refeeding (Fig. 5a).
227 These responses were generally consistent with those semi-quantified by ligand blotting, whereas
228 the latter appeared to be more sensitive in terms of the magnitude of the response (Fig. 5b). In
229 addition, there was a positive correlation between IGFBP-2b levels measured using TR-FIA and
230 ligand blotting (Fig. 5c).

231 Serum IGFBP-2b levels on day 33, as measured using TR-FIA, were positively
232 correlated with SGRs in length during both days 0–33 and 22–33 (Fig. 6a,b). There was also a
233 correlation between the serum IGFBP-2b and IGF-1 levels on day 33 (Fig. 6c). Serum IGFBP-2b
234 levels on day 33 correlated with SGR in weight, whereas the coefficient of correlation appeared
235 to be higher than that measured using ligand blotting (Table 1).
236
237 **4. Discussion**
238 To establish a competitive immunoassay, tracer preparation is critical. Although intact protein
239 purified from the blood is ideal, the amount of purified salmon IGFBP-2b is limited, and purifying
240 it from serum is not practical due to low recovery (Shimizu et al., 2003). The present study utilized
241 recombinant trout (rt) IGFBP-2b to prepare tracers. Two types of rtIGFBP-2b with different
242 fusion partners were prepared for this purpose (Trx.His.rtIGFBP-2b and His.rtIGFBP-2b) and

243 labeled with Eu. However, the recovery of the Eu-His.rtIGFBP-2b from gel filtration was very
244 low, possibly because of adsorption onto the column matrix (data not shown). Thus, only Eu-
245 Trx.His.rtIGFBP-2b was used as the tracer. Although intact salmon IGFBP-2b is *N*-glycosylated
246 while Trx.His.rtIGFBP-2b produced by bacterial cells is not, Eu-labeled Trx.His.rtIGFBP-2b was
247 bound to the antiserum raised against purified Chinook salmon IGFBP-2b (Shimizu et al., 2003),
248 confirming that the lack of glycosylation or addition of a fusion partner did not diminish
249 antigenicity.

250 Trx.His.rtIGFBP-2b was also useful as a standard because its serial dilutions showed
251 a good displacement curve for the tracer in TR-FIA. In contrast, His.rtIGFBP-2b showed little
252 displacement. Such a difference in TR-FIA performance between Trx.His.rtIGFBP-2b and
253 His.rtIGFBP-2b might be due to the degree of protein folding. Generally, linkage to thioredoxin
254 increases the solubility of proteins synthesized in the *E. coli* cytoplasm (LaVallie et al., 1993). In
255 addition, it helps proteins fold correctly (Berndt et al., 2008). Although His.rtIGFBP-2b possessed
256 an IGF-binding ability in ligand blotting (data not shown), its protein folding might have affected
257 its cross-reactivity with antiserum against purified Chinook salmon IGFBP-2b. Based on these
258 results, Trx.His.rtIGFBP-2b was selected as both the tracer and standard.

259 IGF-1 interference in the RIA of salmon IGFBP-2b has been reported previously
260 (Shimizu et al., 2003). This is likely due to a conformational change upon binding to IGF-1 (Arai
261 et al., 1996), which may alter the antigenicity of IGFBPs. This study assessed the possible
262 influence of IGF-1 by adding various amounts of IGF-1 to the serum or standard. Neither the
263 slope of the standard curve nor the measured circulating IGFBP-2b level was affected by the
264 addition of IGF-1. Thus, the interference by IGF-1 in TR-FIA appears to be minimal.

265 TR-FIA is specific enough to measure IGFBP-2b in salmonid blood, in which subtypes
266 of IGFBP-1 are also present. When recombinant masu salmon IGFBP-1b was examined for cross-
267 reactivity with TR-FIA, no displacement was observed. In RIA, the antiserum used in the present
268 study showed only 3% of cross-reactivity with purified Chinook salmon IGFBP-1a and -1b
269 (Shimizu et al., 2003). These findings confirmed the specificity of the antiserum. Given that low
270 cross-reactivity with Chinook salmon IGFBP-1b, we expect that this new TR-FIA will be useful
271 for measurement of IGFBP-2b across salmonids species. The recombinant IGFBP-2b used in the
272 assay was produced based on the sequence from the rainbow trout. Nevertheless, serial dilutions
273 of serum from Chinook salmon and chum salmon showed parallelism with the standard,
274 indicating that TR-FIA is applicable to salmonids other than rainbow trout, as is the case with
275 RIA. However, the potential cross-reactivity with IGFBP-2a should be taken into account.

276 Although IGFBP-2a has not been detected in the circulation of salmonid fishes, it is expressed in
277 the liver and has a 56% deduced amino acid sequence homology with IGFBP-2b (Shimizu et al.,
278 2011b). In rainbow trout and masu salmon sera, the presence of a forth IGFBP band at 32 kDa
279 has been reported (Cleveland et al., 2018; Hayashi et al., 2021; Izustu et al., 2022). If this form is
280 identified as IGFBP-2a, its cross-reactivity in the TR-FIA needs to be tested in future study.
281 Measurement of circulating IGFBP-2b levels using TR-FIA revealed that fasting
282 decreased its levels in immature rainbow trout, which is in good agreement with previous studies
283 (Shimizu et al., 2003, 2009; Cleveland et al., 2020; Izutsu et al., 2022). However, the decreased
284 levels of circulating IGFBP-2b after 22 days of fasting were not restored, even after 11 days of
285 refeeding. As discussed by Izutsu et al. (2022), domesticated rainbow trout selected under
286 intensive feeding might become less adaptive to recovery from fasting conditions.
287 A positive relationship between circulating IGFBP-2b levels measured using TR-FIA
288 and circulating IGF-1 levels was also confirmed. IGFBP-2b in salmonids is thought to be a major
289 carrier of circulating IGF-1 (Shimizu et al., 2003, 2011b, 2017) and there is generally a positive
290 correlation between circulating IGF-1 and IGBP-2b (Beckman et al., 2004a,b). The results of the
291 present study suggest that IGFBP-2b measured using TR-FIA could be a tractable approach for
292 exploring relationships between individual variation in circulating IGFBP-2b levels and growth
293 rate in rainbow trout and other salmonid fishes, with the potential to provide a new physiological
294 growth rate index. Individual variation in IGF-1 is already being used as a growth index in some
295 fishes (Picha et al., 2008; Beckman, 2011) and, based on the patterns observed here (see Fig. 6),
296 measurments of IGFBP-2b may be useful as an additional growth rate marker in salmonid fishes.
297 Notably, the response to fasting and the relationship with the growth rate of IGFBP-2b
298 levels measured using TR-FIA were less sensitive and weaker, respectively, than those measured
299 using ligand blotting. For instance, when rainbow trout were subjected to 22 days of fasting,
300 serum IGFBP-2b levels were 54% lower than those of fed controls in ligand blotting, while only
301 a 17% reduction was observed in TR-FIA. These differences can be attributed to the different
302 principles of these two methods. Ligand blotting detects intact IGFBP with IGF-binding ability
303 after treatment with sodium dodecyl sulfate before electrophoresis, whereas TR-FIA measures
304 both intact and fragmented IGFBP without IGF-binding ability as long as the fragmented IGFBP
305 retains antigenicity (Shimizu et al., 2000; Kaneko et al., 2020). A possible explanation for this
306 discrepancy is that certain parts of the circulating IGFBP-2b are present as fragments and do not
307 respond to fasting. In pregnant women, a considerable portion of circulating IGFBP-3, the major
308 carrier of IGFs, is partly fragmented, which increases the availability of IGFs to the target tissues

309 (Lassarre and Binoux, 2001; Gibson et al., 2001). However, the significance of IGFBP-2b
310 fragmentation in salmon is not known at present and is a subject for future study.
311 In summary, the present study established a TR-FIA for IGFBP-2b using a recombinant
312 protein as the assay component. Although intact IGFBP-2b semi-quantified by ligand blotting
313 may be more sensitive to changes in nutritional and growth status, IGFBP-2b quantified using
314 TR-FIA is also sensitive enough as a growth index and allows the processing of a larger number
315 of samples, making it useful to evaluate the role of IGFBP-2b in modulating growth.
316

317 **5. Acknowledgments**

318 We thank Shu Maruoka, Graudate School of Environmental Science, Hokkaido University, for
319 providing recombinant Atlantic salmon IGFBP-1b1. We acknowledge Editage
320 (www.editage.com) for English language editing. This work was supported by the grant from the
321 Japan Society for the Promotion of Science (JSPS), KAKENHI Grant Number 22H02414.
322

323 **6. References**

324 Arai, T., Busby, W., and Clemmons, D.R., 1996. Binding of insulin-like growth factor (IGF) I or
325 II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix.
326 Endocrinology 137, 4571–4575.
327 Bach, L.A., 2018. IGF-binding proteins. J. Mol. Endocrinol. 6, T11–T28.
328 Baxter, R.C., Martin, J.L., 1989. Binding proteins for the insulin-like growth factors: structure,
329 regulation and function. Prog. Growth Factor Res. 1, 49–68.
330 Beckman, B.R., 2011. Perspectives on concordant and discordant relations between insulin-like
331 growth factor 1 (IGF1) and growth in fishes. Gen. Comp. Endocrinol. 170, 233-252.
332 Beckman, B.R., Shimizu, M., Gadberry, B.A., Cooper, K.A., 2004a. Response of the somatotropic
333 axis of juvenile coho salmon to alterations in plane of nutrition with an analysis of the
334 relationships among growth rate and circulating IGF-I and 41 kDa IGFBP. Gen. Comp.
335 Endocrinol. 135, 334–344.
336 Beckman, B.R., Shimizu, M., Gadberry, B.A., Parkins, P.J., Cooper, K.A., 2004b. The effect of
337 temperature change on the relations among plasma IGF-I, 41-kDa IGFBP, and growth rate
338 in postsmolt coho salmon. Aquaculture 241, 601–619.
339 Berndt, C., Lillig, C.H., Holmgren, A., 2008. Thioredoxins and glutaredoxins as facilitators of
340 protein folding. Biochim. Biophys. Acta 1783, 641–650.
341 Clemmons, D.R., 2018. Role of IGF-binding proteins in regulating IGF responses to changes in

342 metabolism. J. Mol. Endocrinol. 61, T139-T169.
343 Cleveland, B.M., Yamaguchi, G., Radler, L.M., Shimizu, M., 2018. Editing the duplicated insulin-
344 like growth factor binding protein-2b gene in rainbow trout (*Oncorhynchus mykiss*). Sci. Rep.
345 8, 16054.
346 Cleveland, B.M., Habara, S., Oikawa, J., Radler, L.M., Shimizu, M., 2020. Compensatory
347 response of the somatotropic axis from IGFBP-2b gene editing in rainbow trout
348 (*Oncorhynchus mykiss*). Genes 11, 1488.
349 Daughaday, W.H., Rotwein, P., 1989. Insulin-like growth factors I and II. Peptide, messenger
350 ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10, 68–
351 91.
352 de la Serrana, D.G., Macqueen, D.J., 2018. Insulin-like growth factor-binding proteins of teleost
353 fishes. Front. Endocrinol. 9, 80.
354 FAO. 2020. The state of World Fisheries and Aquaculture 2020. Sustainability in action. Rome.
355 Firth, S.M., Baxter, R.C., 2002. Cellular actions of the insulin-like growth factor binding proteins.
356 Endocr. Rev. 23, 824–854.
357 Gibson, J.M., Aplin, J.D., White, A., Westwood, M., 2001. Regulation of IGF bioavailability in
358 pregnancy. Mol. Hum. Reprod. 7, 79–87.
359 Hayashi, M., Maruoka, S., Oikawa, J., Ugachi, Y., and Shimizu, M., Effects of acclimation to
360 diluted seawater on metabolic and growth parameters of underyearling masu salmon
361 (*Oncorhynchus masou*). Zool. Sci. 38, 513-522.
362 Hua, K., Cobcroft, J.M., Cole, A., Condon, K., Jerry, D.R., Mangott, A., Praeger, C., Vucko, M.J.,
363 Zeng, C., Zenger, K., Strugnell, J.M., 2019. The future of aquatic protein: Implications for
364 protein sources in aquaculture diets. One Earth 1, 316–329.
365 Hwa, V., Oh, Y., Rosenfeld, R.G., 1999. The insulin-like growth factor-binding protein (IGFBP)
366 superfamily. Endocr. Rev. 20, 761–87.
367 Izutsu, A., Tadokoro, D., Habara, S., Ugachi, Y., and Shimizu, M., 2022. Evaluation of circulating
368 insulin-like growth factor (IGF)-I and IGF-binding proteins as growth indices in rainbow
369 trout (*Oncorhynchus mykiss*). Gen. Comp. Endocrinol. 320, 114008.
370 Jalili, R., Tukmechi, A., Agh, N., Noori, F., Ghasemi, A., 2013. Replacement of dietary fish meal
371 with plant sources in rainbow trout (Oncorhynchus mykiss); effect on growth performance,
372 immune responses, blood indices and disease resistance. Iran. J. Fish. Sci. 12, 577–591.
373 Kaneko, N., Nilsen, T.O., Tanaka, H., Hara, A., Shimizu, M., 2020. Intact rather than total
374 circulating insulin-like growth factor binding protein-1a is a negative indicator of growth in

375 masu salmon. Am. J. Physiol. Regul. Integr. Comp. Physiol. 318, R329-R337.
376 Kelley, K.M., Siharath, K., Bern, H.A., 1992. Identification of insulin-like growth factor binding
377 proteins in the circulation of four teleost fish species. J. Exp. Zool. 263, 220–224.
378 Kelley, K.M., Haigwood, J.T., Perez, M., Galima, M.M., 2001. Serum insulin-like growth factor
379 binding proteins (IGFBPs) as markers for anabolic/catabolic condition in fishes. Comp.
380 Biochem. Physiol. B 129, 229–236.
381 Lassarre, C., Binoux, M., 2001. Measurement of intact insulin-like growth factor-binding protein-
382 3 in human plasma using a ligand immunofunctional assay. J. Clin. Endocrinol. Metab. 86,
383 1260–1266.
384 LaVallie, E.R., Diblasio, E.A., Kovacic, S., Grant, K.L., Schendel, P.F., and Mccoy, J.M., 1993.
385 A thioredoxin gene fusion expression system that circumvents inclusion body formation in
386 the E. coli cytoplasm. Biotechnology 11, 187–193
387 Macqueen, D.J., Garcia de la serrana, D., Johnston, I.A., 2013. Evolution of ancient functions in
388 the vertebrate insulin-like growth factor system uncovered by study of duplicated salmonid
389 fish genomes. Mol. Biol. Evol. 30, 1060–1076.
390 Mohan, S., Baylink, D.J., 2002. IGF-binding proteins are multifunctional and act via IGF-
391 dependent and – independent mechanisms. J. Endocrinol. 175, 19–31.
392 Ocampo Daza, D., Sundstrom, G., Bergqvist, C.A., Duan, C.M., Larhammar, D., 2011. Evolution
393 of the insulin-like growth factor binding protein (IGFBP) family. Endocrinology 152, 2278–
394 2289.
395 Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, Å., Isgaard, J., Isaksson, O., Jansson, J.O.,
396 Svensson, J., 2009. The role of liver-derived insulin-like growth factor-I. Endocr. Rev. 30,
397 494–535.
398 Picha, M.E., Turano, M.J., Beckman, B.R., Borski, R.J., 2008. Endocrine biomarkers of growth
399 and applications to aquaculture: A minireview of growth hormone, insulin-like growth factor
400 (IGF)-I, and IGF-binding proteins as potential growth indicators in fish. N. Am. J. Aquacult.
401 70, 196-211.
402 Rajaram, S., Baylink, D.J., Mohan, S., 1997. Insulin-like growth factor-binding proteins in serum
403 and other biological fluids: regulation and functions. Endocr. Rev. 18, 801–831.
404 Ranke, M.B., 2015. Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Pract. Res. Clin.
405 Endocrinol. Metab. 29, 701–711.
406 Shimasaki, S., Ling, N., 1991. Identification and molecular characterization of insulin-like growth
407 factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth Factor Res. 3, 243–

408 266.
409 Shimizu, M., Dickhoff, W.W., 2017. Circulating insulin-like growth factor binding proteins in
410 fish: their identities and physiological regulation. Gen. Comp. Endocrinol. 252, 150–161.
411 Shimizu, M., Swanson, P., Fukada, H., Hara, A., Dickhoff, W.W., 2000. Comparison of extraction
412 methods and assay validation for salmon insulin-like growth factor-I using commercially
413 available components. Gen. Comp. Endocrinol. 119, 26–36.
414 Shimizu, M., Hara, A., Dickhoff, W.W., 2003. Development of an RIA for salmon 41 kDa IGF
415 binding protein. J. Endocrinol. 178, 275–283.
416 Shimizu, M., Cooper, K.A., Dickhoff, W.W., Beckman, B.R., 2009. Postprandial changes in
417 plasma growth hormone, insulin, insulin-like growth factor (IGF)-I, and IGF-binding
418 proteins in coho salmon fasted for varying periods. Am. J. Physiol. Regul. Integr. Comp.
419 Physiol. 297, R352–R361.
420 Shimizu, M., Kishimoto, K., Yamaguchi, T., Nakano, Y., Hara, A., Dickhoff, W.W., 2011a.
421 Circulating salmon 28- and 22-kDa insulin-like growth factor binding proteins (IGFBPs) are
422 co-orthologs of IGFBP-1. Gen. Comp. Endocrinol. 174, 97-106.
423 Shimizu, M., Suzuki, S., Horikoshi, M., Hara, A., Dickhoff, W.W., 2011b. Circulating salmon 41
424 kDa insulin-like growth factor binding protein (IGFBP) is not IGFBP-3 but an IGFBP 2
425 subtype. Gen. Comp. Endocrinol. 171, 326–331.
426 Tanaka, H., Oishi, G., Nakano, Y., Mizuta, H., Nagano, Y., Hiramatsu, N., Ando, H., Shimizu, M.,
427 2018. Production of recombinant salmon insulin-like growth factor binding protein-1
428 subtypes. Gen. Comp. Endocrinol 257, 184 –191.
429 Upton, Z., Chan, S.J., Steiner, D.F., Wallace, J.C., Ballard, F.J., 1993. Evolution of insulin-like
430 growth factor binding proteins. Growth Regul. 3, 29–32.
431 Wood, A.W., Duan, C., Bern, H.A., 2005. Insulin-like growth factor signaling in fish. Int. Rev.
432 Cytol. 243, 215–285.
433
434

435 **Figure legends**

436 Fig. 1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), ligand blotting
437 (LB) and immunoblotting (IB) of recombinant trout IGFBP-2b with fusion partners thioredoxin
438 and histidine-tag (Trx.His.rtIGFBP-2b). Four microgams of affinity-purified recombinant protein
439 was separated by 12.5% SDS-PAGE under non-reducing conditions and stained with Coomassie
440 Brilliant Blue (CBB; left panel). Four hundred nanograms of the recombinant protein was
441 electrophored, blotted onto nitrocellulose membranes and subjected to LB using digoxigenin-
442 labeled human IGF-1 (50 ng/ml; middle panel) or IB using antiserum against purified Chinook
443 salmon IGFBP-2b (1:2,500; right panel). Arrows indicate migration positions of the molecular
444 markers (left) and Trx.His.rtIGFBP-2b (right).

445

446 Fig. 2. Displacement of europium-labeled recombinant trout IGFBP-2b with fusion partners
447 thioredoxin and histidine-tag (Trx.His.rtIGFBP-2b) with unlabeled Trx.His.rtIGFBP-2b,
448 His.rtIGFBP-2b, and rainbow trout serum. Binding (B/B_0) is expressed as a percentage of specific
449 binding. All values are means of duplicate determinations.

450

451 Fig. 3. Effects of adding increasing amounts of salmon IGF-1 (0.3 to 80 ng/ml) on the specific
452 binding (B/B_0) of the standard (equivalent to 209 ng/ml) and rainbow trout serum diluted at 1:4.
453 All values are single determinations.

454

455 Fig. 4. Cross-reactivity of recombinant salmon IGFBP-1b (a) and salmon sera (b) in time-resolved
456 fluoroimmunoassay (TR-FIA). Displacement of the tracer was assessed by adding increasing
457 amounts of recombinant Atlantic salmon IGFBP-1b with/without fusion partners Trx and His
458 (31.3 to 500 ng/ml) or serial dilutions of Chinook and chum salmon sera to the assay. All values
459 are means of duplicate determinations.

460

461 Fig. 5. Effects of fasting and refeeding on serum IGFBP-2b levels, measured using time-resolved
462 fluoroimmunoassay (TR-FIA; a) and ligand blotting (b), and their correlation (c). Intensities of
463 the IGFBP-2b bands on ligand blotting were semi-quantified and expressed as arbitrary density
464 units (ADU). Data on ligand blotting were provided by Izutsu et al. (2020). Values are expressed
465 as means ± SE (day 33: $n = 12–14$). Symbols sharing the same letters are not significantly different
466 from each other (Tukey's HSD test, $P < 0.05$). Data from fed (black circules), fasted (white

467 circules) and refed (grey circles) fish were pooled for correlation analysis.

468

469 Fig. 6. Correlations of serum IGFBP-2b level with specific growth rate in length (SGRL) during
470 0–33 days (a) and 22–33 days (b), and with IGF-1 levels (c) in rainbow trout. Data on SGRL were
471 from Izutsu et al. (2022) with permission. Data from fed (black circules), fasted (white circules)
472 and refed (grey circles) fish were pooled for correlation analyses.

Figure 1

Click here to access/download;Figure;Fig1.eps

Izutsu et al., Fig. 1



Izutsu et al., Fig. 2



Figure 3

Click here to access/download;Figure;Fig3.eps

Izutsu et al., Fig. 3



Click here to access/download;Figure;Fig4.eps

Izutsu et al., Fig. 4



Click here to access/download;Figure;Fig5.eps

Izutsu et al., Fig. 5



Figure 6

Click here to access/download;Figure;Fig6.eps

Izutsu et al., Fig. 6



Table (Editable version) Click here to access/download;Table (Editable version);Table 1_revised.docx

Table 1. Correlations of serum IGFBP-2b levels measured by TR-FIA and ligand blotting with IGF-1 level and specific growth rates in length and weight (SGRL and SGRW).

		IGF-1	SGRL		SGRW	
	Day	33	0-33	22-33	0-33	22-33
TR-FIA	r^2	0.45	0.44	0.35	0.37	0.10
	P	< 0.001	< 0.001	0.001	< 0.001	0.051
Ligand blotting	r^2	0.58	0.46	0.34	0.49	0.24
	P	< 0.001	< 0.001	< 0.001	< 0.001	0.0021

Data on serum IGF-1 levels and SGRs are from Izutsu et al. (2022) with permission.

Authors' contributions. A.I.: conceptualization, data curation, methodology, formal analysis, investigation, validation, visualization, writing – original draft. S.H.: methodology, investigation. N.K.: conceptualization, methodology, investigation. D.T.: investigation, resources. A.H.: methodology, investigation. M.S.: conceptualization, data curation, funding acquisition, investigation, project administration, supervision, validation, visualization, writing –original draft, writing – review & editing.

Declaration of interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.